SELECT Trial: Semaglutide for People Without Diabetes The SELECT trial , completed in 2023, was a major study that tested semaglutide in people who were overweight or obese but did not have diabetes
This allows for proper evaluation and necessary modifications to the treatment plan
Patients who discontinued tirzepatide after 36 weeks of weight loss regained approximately half of their lost weight over the following year, while those who continued treatment maintained their results
GLP-1 medicines stimulate insulin release in a glucose-dependent way
We help protect Semaglutide (Ozempic, Rybelsus) and other temperature-sensitive injectables such as: Liraglutide (Victoza, Saxenda) Exenatide (Byetta, Bydureon) Albiglutide (Tanzeum) Dulaglutide (Trulicity) Lixisenatide (Adlyxin) Tirzepatide (Mounjaro, Zepbound) Explore our proven insulated packaging products below, trusted by pharmaceutical companies for safe and efficient GLP-1 drug shipping